サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：液体生検の世界市場- 用途別、対象疾患別、循環バイオマーカーの種類別、試料の種類別、開発段階別、製品種類別、技術別、主要地域別：産業動向と世界予測 (2018年～2035年)
市場調査レポート
商品コード
1398317

液体生検の世界市場- 用途別、対象疾患別、循環バイオマーカーの種類別、試料の種類別、開発段階別、製品種類別、技術別、主要地域別：産業動向と世界予測 (2018年～2035年)

Liquid Biopsy Market : Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, Stage of Development, Type of Product, & Technique, Key Geographical Regions: Industry Trends & Global Forecasts, 2018-2035
出版日: | 発行: Roots Analysis | ページ情報: 英文 331 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
液体生検の世界市場- 用途別、対象疾患別、循環バイオマーカーの種類別、試料の種類別、開発段階別、製品種類別、技術別、主要地域別：産業動向と世界予測 (2018年～2035年)
出版日: 2023年10月26日
発行: Roots Analysis
ページ情報: 英文 331 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の液体生検の市場規模は2023年に54億米ドルとなり、予測期間中 (2023年～2035年) に15.2%のCAGRで成長します。

がんは世界で2番目に多い死亡原因であり、世界の健康への懸念が高まっています。世界保健機関 (WHO) の予測によると、2040年までにがんに関連した死亡者数は1,630万人に達します。がんの種類の中では、乳がんが世界的に最も多く発生し、肺がん、大腸がん、前立腺がんと続きます。Surveillance, Epidemiology, and End Results (SEER) プログラムの統計データによると、女性の乳がん生涯診断率は18%と予想され、2023年には297,790人の新規症例が発生すると予測されています。このような負担の増大に対抗するため、多くのがん研究機関が、がんの早期発見・早期治療をターゲットとした先駆的な手法や患者中心の戦略に積極的に取り組んでいます。がんの早期発見は、治療効果を高め、患者の生存率を高める上で極めて重要な要素です。何十年もの間、組織生検ががん診断の基準となってきました。しかし、この侵襲的な方法には、不快感や痛み、合併症のリスクといった欠点があり、その普及を妨げてきました。それにもかかわらず、近年は液体生検が広く研究されるようになり、がんの診断技術として認知されるようになっています。特に過去10年間は、液体生検プラットフォームの目覚ましい進歩を目の当たりにし、その結果、低侵襲の血液ベースの検査に対する規制当局の承認が増加しました。これらの製品は、がんの早期発見と患者モニタリングのための手段を提供し、アクセスが容易で侵襲が少ないです。こうした検査は血液サンプルや尿や血漿のような体液を利用して、遺伝子変異や、循環腫瘍DNA、無細胞DNA、細胞外小胞を含む様々な循環バイオマーカーを識別します。このような非侵襲的な評価は、特に進行がんの患者にとって、がん治療に革命をもたらしています。

当レポートでは、世界の液体生検の市場について分析し、技術の概略や市場の最新情勢、主な市場促進・抑制要因、昨今の主な資本取引・事業提携の動静、全体的な市場規模の動向見通し、セグメント別・地域別の詳細動向、主要企業のプロファイルなどを調査しております。

市場の主要企業

  • Amoy Diagnostics
  • ArcherDX
  • Biocartis
  • Cell Search
  • CellMax Life
  • Datar Cancer Genetics
  • DiaCarta, EONE-DIAGNOMICS
  • Exosome Diagnostics
  • GeneCast Biotechnology
  • Integrated DNA Technologies
  • Lucence
  • MDNA Life Sciences
  • Miltenyi Biotec
  • NeoGenomics
  • ONCODE Scientific
  • OncoDNA
  • QIAGEN
  • PANAGENE
  • Personal Genome Diagnostics
  • Predicin
  • ScreenCell
  • Tecan
  • Thermo Fisher Scientific

目次

第1章 序文

第2章 分析手法

第3章 経済およびその他のプロジェクト特有の考慮事項

  • 分析概要
  • 市場力学

第4章 エグゼクティブサマリー

第5章 イントロダクション

  • 分析概要
  • がんの統計と病気の負担
  • がんの早期発見の重要性
  • がんのスクリーニングと診断
  • 従来型・侵襲的ながん診断検査
  • 非侵襲的なアプローチの必要性
  • 液体生検：循環バイオマーカーの診断
  • 液体生検と非侵襲的検査に関連するコストと利点
  • 非侵襲的がん診断における最新の知的財産動向
  • 非侵襲的がん診断に伴う課題
  • 将来の展望

第6章 非侵襲がんスクリーニング・診断

  • 分析概要
  • 画像診断
  • スクリーニングアッセイ
  • 高度な非侵襲的アプローチ

第7章 液体生検：市場情勢

  • 分析概要
  • 液体生検製品：全体的な市場情勢
  • 液体生検製品メーカー
  • 液体生検製品：その他の液体生検製品・キット・消耗品
  • 液体生検製品：受託サービスプロバイダー

第8章 企業プロファイル

  • 分析概要
  • 液体生検市場のその他の主要企業

第9章 事業提携・協業

  • 分析概要
  • 事業提携
  • 液体生検：事業提携・協業

第10章 資金調達と投資の分析

  • 分析概要
  • 資金の種類
  • 液体生検：資金調達と投資の分析

第11章 製品の競争力分析

  • 分析概要
  • 調査手法
  • 前提条件と主要パラメーター
  • 液体生検：製品の競争力分析

第12章 大手製薬企業の取り組み

  • 分析概要
  • 大手製薬企業

第13章 企業買収の主要な目標

  • 分析概要
  • 分析範囲・手法
  • 採点基準と重要な前提条件
  • 北米における潜在的な企業買収の対象
  • 欧州における潜在的な企業買収の対象
  • アジア太平洋・その他の地域 (ROW) の潜在的な企業買収の対象
  • 結論

第14章 その他の非侵襲がん診断

  • 分析概要
  • 非血液ベースのバイオマーカー検出検査
  • FOBTおよび糞便免疫化学検査 (FIT)
  • 色素性病変アッセイ
  • 便DNA (sDNA) ベース検査
  • 揮発性有機化合物 (VOC) 検出試験
  • その他の非侵襲がん診断：市場情勢

第15章 市場への影響分析：促進要因、抑制要因、機会、課題

  • 分析概要
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の課題
  • 結論

第16章 世界の液体生検市場

  • 分析概要
  • 重要な前提条件と分析手法
  • 世界の非侵襲がん診断市場 (2023年～2035年)
  • 世界の液体生検市場：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 主要な市場区分
  • ダイナミックダッシュボード

第17章 液体生検市場：用途別

  • 分析概要
  • 重要な前提条件と分析手法
  • がん早期診断：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 患者モニタリング：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 再発モニタリング：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • データの計測と検証

第18章 液体生検市場：対象疾患別

  • 分析概要
  • 重要な前提条件と分析手法
  • 膀胱がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 神経がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 乳がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 子宮頸がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 頭頸部がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 白血病：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 肝臓がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 肺がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 黒色腫：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 上咽頭がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 食道がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 卵巣がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 膵臓がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 前立腺がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 肉腫：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 胃がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 甲状腺がん：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • データの計測と検証

第19章 液体生検市場：循環バイオマーカーの種類別

  • 分析概要
  • 重要な前提条件と分析手法
  • 無細胞 DNA：過去の動向 (2018～2022年) と予測推定値 (2023～2035年)
  • 循環腫瘍DNA：過去の動向 (2018～2022年) と予測推定値 (2023～2035年)
  • 細胞外小胞：過去の動向 (2018～2022年) と予測推定値 (2023～2035年)
  • その他の循環バイオマーカー：過去の動向 (2018～2022年) および予測推定値 (2023～2035年)
  • データの計測と検証

第20章 液体生検市場：試料の種類別

  • 分析概要
  • 重要な前提条件と分析手法
  • 血液/血漿試料：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • その他の試料：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • データの計測と検証

第21章 液体生検市場：エンドユーザーの種類別

  • 分析概要
  • 重要な前提条件と分析手法
  • 病院：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 研究機関：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • その他のエンドユーザー：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • データの計測と検証

第22章 液体生検市場：主要地域別

  • 分析概要
  • 重要な前提条件と分析手法
  • 北米：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • 欧州：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • アジア太平洋・その他の地域 (ROW)：過去の動向 (2018年～2022年) と予測 (2023年～2035年)
  • データの計測と検証

第23章 調査の洞察

  • 分析概要
  • 回答者の所属企業の詳細
  • 回答者の職位別の分析
  • 製品ポートフォリオの種類別の分析
  • 提供製品/サービスの種類別の分析
  • 製品開発段階別の分析
  • 活用領域別の分析
  • 予想される市場規模別の分析

第24章 結論

第25章 経営陣の考察

  • 章の概要
  • Foundation for the National Institutes of Health
  • Bahia Software
  • Genostics
  • Oncophenomics
  • Minomic International
  • IVDiagnostics
  • Tymora Analytical Operations
  • ProXeom
  • MiNDERA
  • Resolution Bioscience
  • Nanostics
  • DermTech
  • iCellate Medical
  • VolitionRx
  • OncoDNA
  • LCM Genect
  • Sienna Cancer Diagnostics

第26章 付録1：表形式のデータ

第27章 付録2：企業・組織の一覧

目次
Product Code: RA100460

The global liquid biopsy market is valued at USD 5.4 billion in 2023 growing at a CAGR of 15.2% during the forecast period 2023-2035.

Cancer stands as the second most prevalent cause of mortality worldwide, presenting an escalating global health concern. Projections by the World Health Organization (WHO) estimate a staggering 16.3 million cancer-related fatalities by 2040. Among the spectrum of cancer types, breast cancer leads as the most commonly occurring globally, trailed by lung, colorectal, and prostate cancers. Statistical data from the Surveillance, Epidemiology, and End Results (SEER) program indicate an anticipated 18% lifetime diagnosis rate for women regarding breast cancer, with an estimated 297,790 new cases anticipated in 2023. To counteract this mounting burden, numerous cancer research institutions actively engage in pioneering methodologies and patient-centric strategies targeting early detection and treatment of cancer. Early identification of cancer constitutes a pivotal factor in bolstering treatment efficacy and augmenting patient survival rates. For decades, tissue biopsy has stood as the benchmark for cancer diagnosis. However, the drawbacks inherent in this invasive procedure-ranging from discomfort, pain to the risk of complications-have impeded its widespread adoption. Nonetheless, extensive exploration into liquid biopsy over recent years has propelled its acknowledgment as a viable diagnostic technique for cancer. The last decade, in particular, has witnessed remarkable advancements in liquid biopsy platforms, resulting in increased regulatory endorsements for minimally invasive blood-based tests. These products present an avenue for early cancer detection and patient monitoring, offering accessibility and minimal invasiveness. Leveraging blood samples or other bodily fluids like urine or plasma, these tests discern genetic mutations and various circulating biomarkers, encompassing circulating tumor DNA, cell-free DNA, and extracellular vesicles. These non-invasive assessments are revolutionizing cancer care, particularly for individuals in advanced cancer stages.

Key Market Segments:

Application

  • Early Cancer Diagnosis
  • Patient Monitoring
  • Recurrence Monitoring

Type of Target Disease Indication

  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Lung Cancer
  • Prostate cancer
  • Others

Type of Circulating Biomarker

  • Cell Free DNA
  • Cell Free RNA
  • Circulating Tumor DNA
  • Extracellular Vesicles
  • Other Circulating Biomarkers

Type of Sample

  • Blood / Plasma
  • Other Analytes

End User

  • Hospitals
  • Research Institutes
  • Others

Key Geographical Regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • The report studies the liquid biopsy market based on application, target disease indication, type of circulating biomarker, type of sample, end users, stage of development, type of product, type of technique, application area and key geographical regions
  • The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
  • The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
  • The report forecasts the revenue of market segments with respect to four major regions
  • A detailed outline of the research approach employed for studying the liquid biopsy market and non-invasive cancer diagnostics. This includes methodologies, assumptions, and quality control measures adopted to ensure the reliability and accuracy of findings.
  • Examination of historical trends, currency fluctuations, foreign exchange impacts, recessions, and inflation measurements that influence the overall liquid biopsy market.
  • Concise summary capturing key insights from the research, providing a high-level view of the current status of the liquid biopsy market and its anticipated evolution in the short, mid, and long terms.
  • Overview of cancer statistics, emphasizing the global disease burden, the significance of early cancer detection and screening, and insights into different types of circulating biomarkers based on their functionality. Additionally, exploration of emerging trends in intellectual property related to non-invasive cancer diagnostics, liquid biopsy costs, benefits, challenges, and their importance.
  • Emphasis on the necessity and significance of non-invasive cancer diagnostics, inclusive of various imaging techniques, screening assays, advanced diagnostic approaches, along with their respective advantages and disadvantages.
  • Detailed assessment of the liquid biopsy product market based on multiple parameters like development stage, product types (assay kits, devices, software/algorithms), sample types, techniques used, circulating biomarkers, target disease indications, applications, and players involved.
  • Tabulated profiles of leading liquid biopsy companies focusing on their establishment, workforce, headquarters, financial performance, product portfolio, recent developments, and future outlook.
  • Examination of recent collaborations within the liquid biopsy market, considering parameters such as partnership types, circulating biomarkers, target disease indications, most active players, and regional distributions.
  • In-depth analysis of funding and investments in liquid biopsy companies between 2016 and 2023, considering various parameters like funding types, target disease indications, application areas, geographic distribution, leading investors, and notable funding instances.
  • Detailed evaluation of liquid biopsy product competitiveness based on supplier strength, product attributes, company size, and technological advancements.
  • Comprehensive analysis of initiatives by major pharmaceutical companies, focusing on areas of interest, stages of development, product types, target indications, and application areas.
  • Review of historical acquisition activities since 2016, identifying potential acquisition targets within the industry.
  • Detailed insight into various non-invasive diagnostic tests, besides liquid biopsies, offered by different companies for cancer screening and early detection.
  • In-depth examination of growth factors, potential limitations, emerging opportunities, and existing challenges influencing the liquid biopsy market.

Key Benefits of Buying this Report:

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the liquid bipsy market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies:

  • Amoy Diagnostics
  • ArcherDX
  • Biocartis
  • Cell Search
  • CellMax Life
  • Datar Cancer Genetics
  • DiaCarta, EONE-DIAGNOMICS
  • Exosome Diagnostics
  • GeneCast Biotechnology
  • Integrated DNA Technologies
  • Lucence
  • MDNA Life Sciences
  • Miltenyi Biotec
  • NeoGenomics
  • ONCODE Scientific
  • OncoDNA
  • QIAGEN
  • PANAGENE
  • Personal Genome Diagnostics
  • Predicin
  • ScreenCell
  • Tecan
  • Thermo Fisher Scientific

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Chapter Overview
  • 1.2. Project Objectives
  • 1.3. Scope of the Report
  • 1.4. Inclusions and Exclusions
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Cancer Statistics and Burden of the Disease
  • 5.3. Importance of Early Cancer Detection
  • 5.4. Cancer Screening and Diagnosis
  • 5.5 Conventional Invasive Cancer Diagnostic Tests
    • 5.5.1. Biopsy
    • 5.5.2. Fine Needle Aspiration Biopsy
    • 5.5.3. Core Needle Aspiration Biopsy
    • 5.5.4. Vacuum-Assisted Biopsy
    • 5.5.5. Image Guided Biopsy
    • 5.5.6. Sentinel Node Biopsy
    • 5.5.7. Surgical Biopsy
    • 5.5.8. Endoscopic Biopsy
    • 5.5.9. Bone Marrow Biopsy
    • 5.5.10. Endoscopy
  • 5.6. Need for Non-Invasive Approaches
  • 5.7. Liquid Biopsy: Diagnosing Circulating Biomarkers
    • 5.7.1 Circulating Tumor Cells
    • 5.7.2. Circulating Tumor DNA/ Cell Free DNA
    • 5.7.3. Exosomes
  • 5.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests
  • 5.9. Latest Intellectual Property Trends in Non-Invasive Cancer Diagnostics
  • 5.10. Challenges Associated with Non-Invasive Cancer Diagnostics
  • 5.11. Future Perspectives

6. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

  • 6.1. Chapter Overview
  • 6.2. Diagnostic Imaging
    • 6.2.1. Magnetic Resonance Imaging (MRI)
    • 6.2.2. Mammography
    • 6.2.3. Bone Scan
    • 6.2.4. Computerized Tomography (CT) Scan
    • 6.2.5. Integrated Positron Emission Tomography (PET)- CT Scan
    • 6.2.6. Ultrasound
    • 6.2.7. X-ray Radiography (Barium Enema)
  • 6.3. Screening Assays
    • 6.3.1. Circulating Tumor Marker Test
    • 6.3.2. Digital Rectal Exam (DRE)
    • 6.3.3. Fecal Occult Blood Test (FOBT)
    • 6.3.4. Multigated Acquisition (MUGA) Scan
    • 6.3.5. Papanicolaou Test and Human Papilloma Virus Test
  • 6.4. Advanced Non-Invasive Approaches
    • 6.4.1. Cytogenetic / Gene Expression Studies
    • 6.4.2. Molecular Signature-based Non-Invasive Methods
    • 6.4.3. Saliva-based Oral Cancer Diagnostics
    • 6.4.4. Vital Staining
    • 6.4.5. Optical Biopsy
    • 6.4.6 Other Diagnostic Techniques

7. LIQUID BIOPSY: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Liquid Biopsy Products: Overall Market Landscape
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Type of Product
    • 7.2.3. Analysis by Type of Sample
    • 7.2.4. Analysis by Type of Technique
    • 7.2.5. Analysis by Type of Circulating Biomarker
    • 7.2.6. Analysis by Tumor
    • 7.2.7. Analysis by Target Disease Indication
    • 7.2.8. Analysis by Application
    • 7.2.9. Analysis by Application Area
  • 7.3. Liquid Biopsy Product Manufacturers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters (Region)
    • 7.3.3. Analysis by Location of Headquarters (Country)
    • 7.3.4. Most Active Players: Analysis by Number of Liquid Biopsy Products
  • 7.4. Liquid Biopsy Products: Other Liquid Biopsy Products, Kits and Consumables
  • 7.5. Liquid Biopsy Products: Contract Service Providers

8. COMPANY PROFILES

  • 8.1. Chapter Overview
    • 8.2.1. Amoy Diagnostics
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Product Portfolio
      • 8.2.1.3. Recent Developments and Future Outlook
    • 8.2.2. ArcherDX
      • 8.2.2.1. Company Overview
      • 8.2.2.2 Product Portfolio
      • 8.2.2.3. Recent Developments and Future Outlook
    • 8.2.3. DiaCarta
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Product Portfolio
      • 8.2.3.3 Recent Developments and Future Outlook
    • 8.2.4. Integrated DNA Technologies
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Product Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5 MDNA Life Sciences
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Information
      • 8.2.5.3 Product Portfolio
      • 8.2.5.4. Recent Developments and Future Outlook
    • 8.2.6. NeoGenomics
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Product Portfolio
      • 8.2.6.3. Recent Developments and Future Outlook
    • 8.2.7. ONCODE Scientific
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Product Portfolio
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. QIAGEN
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Information
      • 8.2.8.3. Product Portfolio
      • 8.2.8.4. Recent Developments and Future Outlook
    • 8.2.9. ScreenCell
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Information
      • 8.2.9.3. Product Portfolio
      • 8.2.9.4. Recent Developments and Future Outlook
    • 8.2.10. Thermo Fisher Scientific
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Information
      • 8.2.10.3. Product Portfolio
      • 8.2.10.4. Recent Developments and Future Outlook
  • 8.3. Other Leading Players in Liquid Biopsy Market
    • 8.3.1. Biocartis
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Product Portfolio
    • 8.3.2. Cell Search
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Product Portfolio
    • 8.3.3. CellMax Life
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Product Portfolio
    • 8.3.4. Datar Cancer Genetics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Product Portfolio
    • 8.3.5. EONE-DIAGNOMICS Genome Center
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Product Portfolio
    • 8.3.6. Exosome Diagnostics
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Product Portfolio
    • 8.3.7. GeneCast Biotechnology
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Product Portfolio
    • 8.3.8. Inivata
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Product Portfolio
    • 8.3.9. Lucence
      • 8.3.90.1. Company Overview
      • 8.3.9.2. Product Portfolio
    • 8.3.10. Miltenyi Biotec
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Product Portfolio
    • 8.3.11. OncoDNA
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Product Portfolio
    • 8.3.12. PANAGENE
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Product Portfolio
    • 8.3.13. Personal Genome Diagnostics
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Product Portfolio
    • 8.3.14. Predicine
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Product Portfolio
    • 8.3.15. Tecan
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Product Portfolio

9. PARTNERSHIPS AND COLLABORATIONS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Liquid Biopsy: Partnerships and Collaborations
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Year and Type of Partnership
    • 9.3.4. Analysis by Type of Partner
    • 9.3.5. Analysis by Year of Partnership and Type of Partner
    • 9.3.6. Analysis by Type of Partnership and Type of Partner
    • 9.3.7. Analysis by Type of Circulating Biomarker
    • 9.3.8. Analysis by Target Disease Indication
    • 9.3.9. Most Active Players: Analysis by Number of Partnerships
    • 9.3.10. Analysis by Geography
      • 9.3.10.1. Local and International Agreements
      • 9.3.10.2 Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Types of Funding
  • 10.3. Liquid Biopsy: Funding and Investment Analysis
    • 10.3.1. Analysis by Year of Investment
    • 10.3.2. Analysis of Amount Invested by Year
    • 10.3.3. Analysis by Type of Funding
    • 10.3.4. Analysis of Amount Invested by Type of Funding
    • 10.3.5. Analysis by Year and Type of Funding
    • 10.3.6. Analysis by Type of Circulating Biomarker
    • 10.3.7. Analysis by Target Disease Indication
    • 10.3.8. Analysis by Application Area
    • 10.3.9. Analysis by Geography
    • 10.3.10. Most Active Players: Analysis by Number of Funding Instances
    • 10.3.11. Most Active Players: Analysis by Amount Raised
    • 10.3.12. Most Active Investors: Analysis by Number of Funding Instances

11. PRODUCT COMPETITIVENESS ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Methodology
  • 11.3. Assumptions and Key Parameters
  • 11.4. Liquid Biopsy: Product Competitiveness Analysis
    • 11.4.1. Liquid Biopsy Assay Kits
      • 11.4.1.1. Products Offered by Players based in North America
      • 11.4.1.2. Products Offered by Players based in Europe
      • 11.4.1.3. Products Offered by Players based in Asia-Pacific
      • 11.4.1.4. Products Offered by Players based in Rest of the World
    • 11.4.2. Liquid Biopsy Devices
      • 11.4.2.1. Products Offered by Players based in North America
      • 11.4.2.2. Products Offered by Players based in Europe and Asia-Pacific
    • 11.4.3. Liquid Biopsy Software

12. BIG PHARMA INITIATIVES

  • 12.1. Chapter Overview
  • 12.2. Top Pharmaceutical Companies
    • 12.2.1. Analysis by Type of Initiative
    • 12.2.2. Analysis by Stage of Development
    • 12.2.3. Analysis by Type of Product
    • 12.2.4. Analysis by Type of Circulating Biomarker
    • 12.2.5. Analysis by Target Disease Indication
    • 12.2.6. Analysis by Application
    • 12.2.7. Analysis by Application Area

13. KEY ACQUISITION TARGETS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Scoring Criteria and Key Assumptions
  • 13.4. Potential Acquisition Targets in North America
  • 13.5. Potential Acquisition Targets in Europe
  • 13.6. Potential Acquisition Targets in Asia-Pacific and Rest of the World
  • 13.7. Concluding Remarks

14. OTHER NON-INVASIVE CANCER DIAGNOSTICS

  • 14.1. Chapter Overview
  • 14.2. Non-Blood-based Biomarker Detection Tests
  • 14.3. FOBT and Fecal Immunochemical Tests (FIT)
  • 14.4. Pigmented Lesion Assays
  • 14.5. Stool DNA (sDNA)-based Tests
  • 14.6. Volatile Organic Compound (VOC) Detection Tests
  • 14.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Chapter Overview
  • 15.2. Market Drivers
  • 15.3. Market Restraints
  • 15.4. Market Opportunities
  • 15.5. Market Challenges
  • 15.6. Conclusion

16. GLOBAL LIQUID BIOPSY MARKET

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Global Non-Invasive Cancer Diagnostics Market, (2023-2035)
  • 16.4. Global Liquid Biopsy Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
    • 16.4.1. Scenario Analysis
  • 16.5. Key Market Segmentations
  • 16.6. Dynamic Dashboard

17. LIQUID BIOPSY MARKET, BY APPLICATION

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Early Cancer Diagnosis: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.4. Patient Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.5. Recurrence Monitoring: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 17.6. Data Triangulation and Validation

18. LIQUID BIOPSY MARKET, BY TARGET DISEASE INDICATION

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Bladder Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.4. Neurological Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.5. Breast Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.6. Cervical Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.7. Head and Neck Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.8. Leukemia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.9. Liver Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.10. Lung Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.11. Melanoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.12. Nasopharyngeal Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.13. Oesophagus Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.14. Ovarian Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.15. Pancreatic Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.16. Prostate Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.17. Sarcoma: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.18. Stomach Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.19. Thyroid Cancer: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 18.20. Data Triangulation and Validation

19. LIQUID BIOPSY MARKET, BY TYPE OF CIRCULATING BIOMARKER

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Cell-Free DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.4. Circulating Tumor DNA: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.5. Extracellular Vesicles: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.6. Other Circulating Biomarkers: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 19.7. Data Triangulation and Validation

20. LIQUID BIOPSY MARKET, BY TYPE OF SAMPLE

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Blood / Plasma Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.4. Other Samples: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 20.5. Data Triangulation and Validation

21. LIQUID BIOPSY MARKET, BY TYPE OF END-USER

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Hospitals: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.4. Research Institutes: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.5. Other End-users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 21.6. Data Triangulation and Validation

22. LIQUID BIOPSY MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.5. Asia-Pacific and Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
  • 22.6. Data Triangulation and Validation

23. SURVEY INSIGHTS

  • 23.1. Chapter Overview
  • 23.2. Company Specifics of Respondents
  • 23.3. Analysis by Seniority Level of Respondents
  • 23.4. Analysis by Type of Product Portfolio
  • 23.5. Analysis by Type of Products / Services Offered
  • 23.6. Analysis by Stage of Development of Product
  • 23.7. Analysis by Application Area
  • 23.8. Analysis by Likely Market Size

24. CONCLUSION

25. EXECUTIVE INSIGHTS

  • 25.1. Chapter Overview
  • 25.2. Foundation for the National Institutes of Health
    • 25.2.1. Company Snapshot
    • 25.2.2. Interview Transcript
  • 25.3. Bahia Software
    • 25.3.1. Company Snapshot
    • 25.3.2. Interview Transcript
  • 25.4. Genostics
    • 25.4.1. Company Snapshot
    • 25.4.2. Interview Transcript
  • 25.5. Oncophenomics
    • 25.5.1. Company Snapshot
    • 25.5.2. Interview Transcript
  • 25.6. Minomic International
    • 25.6.1. Company Snapshot
    • 25.6.2. Interview Transcript
  • 25.7. IVDiagnostics
    • 25.7.1. Company Snapshot
    • 25.7.2. Interview Transcript
  • 25.8. Tymora Analytical Operations
    • 25.8.1. Company Snapshot
    • 25.8.2. Interview Transcript
  • 25.9. ProXeom
    • 25.9.1. Company Snapshot
    • 25.9.2. Interview Transcript
  • 25.10. MiNDERA
    • 25.10.1. Company Snapshot
    • 25.10.2. Interview Transcript
  • 25.11. Resolution Bioscience
    • 25.11.1. Company Snapshot
    • 25.11.2. Interview Transcript
  • 25.12. Nanostics
    • 25.12.1. Company Snapshot
    • 25.12.2. Interview Transcript
  • 25.13. DermTech
    • 25.13.1. Company Snapshot
    • 25.13.2. Interview Transcript
  • 25.14. iCellate Medical
    • 25.14.1. Company Snapshot
    • 25.14.2. Interview Transcript
  • 25.15. VolitionRx
    • 25.15.1. Company Snapshot
    • 25.15.2. Interview Transcript
  • 25.16. OncoDNA
    • 25.16.1. Company Snapshot
    • 25.16.2. Interview Transcript
  • 25.17. LCM Genect
    • 25.17.1. Company Snapshot
    • 25.17.2. Interview Transcript
  • 25.18. Sienna Cancer Diagnostics
    • 25.18.1. Company Snapshot
    • 25.18.2. Interview Transcript

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS